How to buy ALX Oncology stock - 21 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ALX Oncology stock

Own ALX Oncology stock in just a few minutes.

ALX Oncology Holdings Inc is a biotechnology business based in the US. ALX Oncology shares (ALXO) are listed on the NASDAQ and all prices are listed in US Dollars. ALX Oncology employs 23 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in ALX Oncology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ALXO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

ALX Oncology share price

Use our graph to track the performance of ALXO stocks over time.

ALX Oncology shares at a glance

Information last updated 2021-04-15.
52-week range$28.01 - $110.00
50-day moving average $72.69
200-day moving average $68.45
Wall St. target price$98.43
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.74

Buy ALX Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ALX Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ALX Oncology financials

Revenue TTM $1.2 million
Gross profit TTM $107,000
Return on assets TTM -12.22%
Return on equity TTM -21.3%
Profit margin 0%
Book value N/A
Market capitalisation $2.4 billion

TTM: trailing 12 months

Shorting ALX Oncology shares

There are currently 2.3 million ALX Oncology shares held short by investors – that's known as ALX Oncology's "short interest". This figure is 76.4% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting ALX Oncology shares can be evaluated.

ALX Oncology's "short interest ratio" (SIR)

ALX Oncology's "short interest ratio" (SIR) is the quantity of ALX Oncology shares currently shorted divided by the average quantity of ALX Oncology shares traded daily (recently around 361502.22222222). ALX Oncology's SIR currently stands at 6.3. In other words for every 100,000 ALX Oncology shares traded daily on the market, roughly 6300 shares are currently held short.

However ALX Oncology's short interest can also be evaluated against the total number of ALX Oncology shares, or, against the total number of tradable ALX Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ALX Oncology's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 ALX Oncology shares in existence, roughly 60 shares are currently held short) or 0.0957% of the tradable shares (for every 100,000 tradable ALX Oncology shares, roughly 96 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ALX Oncology.

Find out more about how you can short ALX Oncology stock.

ALX Oncology share dividends

We're not expecting ALX Oncology to pay a dividend over the next 12 months.

ALX Oncology overview

ALX Oncology Holdings Inc. , a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site